I had guesstimated the generic market being approximately 1B, and if approved Elite being able to capture 5% of that market, or 50 million. Divide that by 4 (12.5), and tag that to a guesstimate of 12 mil/quarter current revenue, and just that alone gets us to 100 million/year. There is a lot of potential with all that Elite has in the works. I'm excited to see how it all unfolds in the next few months to 3 years. 8 cents is still quite below where we should be NOW, imo.
Agreed, I think we can capture a little more of the market, but not expecting 10%. I’m expecting Vyvanse to give a huge shot in the arm to R&D, buyback, next mfg facility, etc. My biggest concern at this point is that company is sold too early before executing current pipeline and before R&D really gets humming.
News 
Market Data 
Discover 
